Guillermo Chantada, Head of the Outreach Program at Hospital Sant Joan de Déu and Scientific Director of the Perez Scremini Foundation, shared a post on LinkedIn about a recent article by Gabriela I. Villanueva et al, published in JCO Global Oncology:
“It is not so common to find papers about neuroblastoma from Latin America.
It is even less common if they are consensus about the use of immunotherapy. This is a great effort of most of the people who treats neuroblastoma in the continent, especially by Gabriela Villanueva with a great contribution of Scott Howard who manage to invite all the key opinion leaders to this seminal paper.
We now need to improve access, find the ways for the implementation of the use of these drugs to cause the greater impact in survival and move on to advance the cure of this tumor.”
Title: Latin American Consensus on the Use of Anti-GD2 Monoclonal Antibody Therapy in Patients With High-Risk Neuroblastoma
Authors: Gabriela I. Villanueva, Sandra Alarcón, Diana Bonilla, Alejandra Casanovas, Mauricio Chaparro, Marcelo D. Coirini, Guido Felizzia, Diego Figueredo, Soad Fuentes-Alabi, Sima Ferman, Simone Franco, Mercedes Garcia Lombardi, Félix Gaytan Morales, Lauro J. Gregianin, Óscar González Ramella, Nathalia Halley, Camila Hashimoto, Arissa Ikeda, Scott Howard, Luis E. Juárez Villegas, Fabiana Morosini, Alberto Olaya Vargas, Vicente Odone-Filho, Nevicolino Pereira de Carvalho Filho, Catalina Peters, Veronica Pérez, Martín Pérez García, Agustina Pollono, Roy Rosado, Lourdes Romero, Haydeé del Pilar Salazar Rosales, Beatriz Silva, Victoria Sobrero, Delia P. Streitenberger, Diana Valencia, Mariana Varela, Milena Villarroel
Read the Full Article on JCO Global Oncology
More posts featuring Guillermo Chantada.